China has approved a new GLP 1 based drug developed by Pfizer for long term weight management in adults who are overweight or obese, marking another step in the rapid expansion of the country’s metabolic health treatment market. The approval allows the injectable
Hong Kong listed biotechnology company Insilico Medicine has expanded its global footprint through a new partnership in the United Arab Emirates aimed at accelerating artificial intelligence driven drug discovery. The agreement was signed with the UAE’s national drug regulator during a major healthcare
China and Hong Kong are being encouraged to relax listing requirements for biotechnology companies as investors seek to accelerate growth in the healthcare sector. Venture capital leaders and industry participants argue that regulatory adjustments could help innovative biotech firms gain faster access to
China’s biotechnology sector has recorded a sharp rise in international licensing deals during the opening months of 2026, highlighting the country’s growing influence in global pharmaceutical research and drug development. The total value of outlicensing agreements signed by Chinese biotech companies in the
Diagnostics startup Droplet Biosciences has announced a collaboration with Nvidia to accelerate the processing of genomic data used in post surgery cancer testing, aiming to significantly shorten the time patients wait for critical results. The company is integrating Nvidia’s GPU accelerated computing infrastructure,
Chinese artificial intelligence driven drug discovery firm XtalPi Holdings has projected its first full year profit following a sharp rise in revenue, signaling growing commercial traction for AI powered pharmaceutical research in China. The Shenzhen based company said it expects to report a
China’s biotechnology sector is entering a new phase of financial maturity as companies move beyond heavy reliance on licensing agreements and tap deeper pools of domestic and international capital. Strong equity market performance, regulatory reforms and expanding innovation pipelines are reshaping the funding
Chinese biotechnology companies are accelerating their push into global markets, with Shanghai based Harbour BioMed announcing a partnership valued at more than US$1.2 billion to advance one of its clinical stage antibody therapies outside mainland China. The agreement underscores a broader shift in
China’s accelerating biotechnology expansion is driving an unexpected cost surge in one of the industry’s most critical research resources, laboratory monkeys used in preclinical drug testing. Prices for experimental monkeys have climbed to around 140,000 yuan per animal, a level that now exceeds
China’s biotechnology sector is on track for another record year in licensing activity as global pharmaceutical companies intensify their search for innovative drug candidates to offset looming patent expirations and rising research costs. Data from industry tracker Pharmcube shows that out licensing deals
